Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,148
datasets available to search
ShareScore release 0.9.0
Dataset results
2,148 results for “HER2”
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
ClinicalTrials.gov study NCT00509769. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m
ClinicalTrials.gov study NCT05141708. IPD Sharing: NO. Countries: 1. Publications: 0.
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
ClinicalTrials.gov study NCT06144944. IPD Sharing: YES. Countries: 1. Publications: 0.
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
ClinicalTrials.gov study NCT01421472. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
ClinicalTrials.gov study NCT01388647. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
ClinicalTrials.gov study NCT04937660. IPD Sharing: NO. Countries: 5. Publications: 0.
An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)
ClinicalTrials.gov study NCT02658461. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
ClinicalTrials.gov study NCT00679029. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
ClinicalTrials.gov study NCT01527487. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced
ClinicalTrials.gov study NCT02964507. IPD Sharing: YES. Countries: 7. Publications: 0.
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Bre
ClinicalTrials.gov study NCT04915755. IPD Sharing: YES. Countries: 27. Publications: 0.
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aroma
ClinicalTrials.gov study NCT05038735. IPD Sharing: YES. Countries: 17. Publications: 0.
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC
ClinicalTrials.gov study NCT03910712. IPD Sharing: NO. Countries: 0. Publications: 1.
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
ClinicalTrials.gov study NCT06731478. IPD Sharing: YES. Countries: 26. Publications: 0.
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
ClinicalTrials.gov study NCT02120417. IPD Sharing: Not stated. Countries: 6. Publications: 0.
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
ClinicalTrials.gov study NCT00634088. IPD Sharing: Not stated. Countries: 3. Publications: 0.
MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer
ClinicalTrials.gov study NCT01097460. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carc
ClinicalTrials.gov study NCT05488353. IPD Sharing: NO. Countries: 0. Publications: 2.
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
ClinicalTrials.gov study NCT05721248. IPD Sharing: YES. Countries: 1. Publications: 0.
Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility
ClinicalTrials.gov study NCT00591851. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.